Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

104.05 +3.62 (+3.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 782,112
Open 101.00
Bid (Size) 95.75 (1)
Ask (Size) 105.00 (18)
Prev. Close 100.43
Today's Range 99.54 - 104.05
52wk Range 64.33 - 127.77
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Recap: Ascendis Pharma Q3 Earnings
Via Benzinga

Performance

YTD
-13.81%
-13.81%
1 Month
+14.61%
+14.61%
3 Month
+5.88%
+5.88%
6 Month
+13.96%
+13.96%
1 Year
-14.54%
-14.54%

More News

Read More
Preview: Ascendis Pharma's Earnings
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Earnings Preview For Ascendis Pharma
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Where Ascendis Pharma Stands With Analysts
Via Benzinga
Earnings Scheduled For September 5, 2023
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
Via Benzinga
Why Shares of Ascendis Pharma Are Climbing Monday
Via The Motley Fool
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
Via Benzinga
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
Via SBWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
Via NewMediaWire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.